Mark Enyedy possesses extensive executive leadership experience in the biotechnology and pharmaceutical sectors, currently serving as an Independent Director at BioMarin Pharmaceutical Inc. and a Non-Executive Director at ERGOMED. Previous roles include President and CEO of ImmunoGen, Inc., and EVP and Head of Corporate Development at Shire Pharmaceuticals. Mark also held key leadership positions at Proteostasis Therapeutics, Inc. and Genzyme, overseeing major therapeutic areas. Academic credentials include a Doctor of Law (JD) from Harvard Law School.